C4 Therapeutics, Inc. (CCCC) is a leading biopharmaceutical company that is revolutionizing the treatment of cancer and other life-threatening diseases through an innovative, targeted protein degradation (TPD) technology. Incorporated in 2015 and based in the biotech hub of Cambridge, Massachusetts, the company is publicly traded under the ticker symbol CCCC on the NASDAQ stock exchange.
C4 Therapeutics is recognized for its advanced research and development of small molecule drugs that leverage the body's natural protein disposal system. Utilizing their proprietary DEGRONIMID™ platform, they develop treatments that selectively tag disease-causing proteins for degradation, thereby disrupting their activities. This unique technology provides numerous advantages over traditional therapies, including increased efficacy, higher specificity, and reduced cytotoxic effects.
C4 Therapeutics is pioneering this transformative approach to therapy across several therapeutic areas. The company’s robust drug discovery engine and broad intellectual property portfolio have led to a diverse pipeline of product candidates addressing multiple indications, primarily in oncology such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and prostate cancer. These therapies are designed to overcome limitations of current treatment options and offer hope to patients who have run out of options.
The company's collaborative approach is another hallmark of its strategy. They have established several strategic partnerships with leading pharmaceutical companies, including Roche and Calico, that accelerate development and enable C4 Therapeutics to pursue a range of disease targets.
C4 Therapeutics follows a relentless commitment to scientific excellence, patient safety and ethical business conduct. The company's team consists of world-class scientists, clinicians, and professionals committed to making a transformative impact on patient care. At C4 Therapeutics, unmet medical needs drive innovation, and the ultimate goal is to improve and extend the lives of patients around the globe.
Despite the extremely complex and high-risk nature of drug development, C4 Therapeutics has so far exhibited promising potential. The company has already attracted significant interest from investors, buoyed by the desire for innovative and effective treatments for cancer and other serious diseases. The company's growth and development are anticipated to continue in the years to come as they work towards bringing their groundbreaking therapies from bench to bedside.
In conclusion, C4 Therapeutics, Inc. (CCCC) is at the forefront of the biopharmaceutical industry as they champion a revolutionary technology poised to improve the lives of patients burdened with cancer and other life-threatening diseases. They are an exemplar of innovative thinking, strategic collaboration, and a relentless pursuit of life-changing therapies.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
C4 Therapeutics (Nasdaq: CCCC) presented new biomarker data from its Phase 1 trial of cemsidomide with dexamethasone and preliminary data from its Phase 1b trial with elranatamab for relapsed/refractory multiple myeloma at the 23rd IMS Annual Meeting. The data highlights cemsidomide's immunomodulatory effects, including T-cell activation and prevention of T-cell exhaustion, suggesting its potential to enhance immune-based therapies. The 75 µg cemsidomide dose level in the Phase 1b trial was declared safe, allowing advancement to dose escalation and expansion cohorts, with further data expected mid-2027.
C4 Therapeutics CFO Kendra Adams recently reported two stock transactions involving RSU vesting and tax withholding. On September 18, 2026, Adams acquired 6,250 common shares from vested restricted stock units and had 2,775 shares withheld at $3.39 each to cover tax liabilities. Following these transactions, Adams directly holds 382,323 shares of C4 Therapeutics common stock.
C4 Therapeutics is currently rated as a Hold due to its valuation being heavily dependent on the Phase 2 success of its primary asset, cemsidomide. The company possesses $300.4 million in cash, providing financial stability until late 2028 to support its clinical and partnered programs. While its fair value is calculated at $3.32 per share, below the current price of $3.71, a successful outcome from the Phase 2 MOMENTUM trial data in late 2027 could significantly increase the fair value to $5.32 per share.
C4 Therapeutics (C4T) will present new biomarker data on cemsidomide's immunomodulatory effects in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) at the 23rd IMS Annual Meeting. The data highlights cemsidomide's impact on T cells and natural killer (NK) cells, supporting its potential as a partner for immune-based therapies. Cemsidomide is an investigational orally bioavailable MonoDAC® degrader of IKZF1/3, showing a differentiated safety profile and anti-myeloma activity.